MHRA-101111-PIP01-23

Key Facts

Active Substance
Active Substance:
  • Cendakimab (BMS-986355)
Invented Name
Not yet available
PIP Number MHRA-101111-PIP01-23
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
Therapeutic area:
  • Immunology -Rheumatology-Transplantation
Conditions / Indications
Conditions / Indications:
  • Treatment of Eosinophilic Esophagitis (EoE)
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Cendakimab (BMS-986355).pdf
Published Date 03/10/2024